UPDATE: FDA approves Vertex Incivek for hepatitis C

U.S. Food and Drug Administration today approved Incivek (telaprevir) to treat certain adults with chronic hepatitis C infection. Incivek is used for patients who have either not received interferon-based drug therapy for their infection or who have not responded adequately to prior therapies. Incivek is approved for use with interferon therapy made up of peginterferon alfa and ribavirin. Incivek is marketed by Cambridge, Mass.-based Vertex Pharmaceuticals VRTX.